Development of endothelin receptor antagonists as potential therapeutic agents

Adviye Ergul

Research output: Contribution to journalReview article

7 Citations (Scopus)

Abstract

Endothelin-1 (ET-1), a potent vasoconstrictor and mitogen, is associated with several disease states including pulmonary hypertension, systemic hypertension and heart failure. There are two endothelin (ET) receptor subtypes known as ET A and ET B . Selective ET A receptor antagonists, as well as non-selective (dual) ET A /ET B antagonists, represent a new therapeutic target for disease states associated with elevated ET-1 levels. In vivo studies and early phase clinical trials have provided strong evidence that these agents are effective in the treatment of heart failure, essential hypertension, pulmonary hypertension and atherosclerosis. FDA approved the use of the orally active dual antagonist bosentan (Tracleer™, Roche Holding AG) for primary pulmonary hypertension in 2001. Despite important advances in this field, the complexity of biological effects mediated by two different receptor subtypes complicates the use of selective versus dual ET receptor antagonists. The number of patent applications filed in recent years emphasises the importance of this emerging class of therapeutics. From 1997 to date, ∼ 192 patents have been filed. In this review, compounds patented between 1999 and 2002 will be reviewed and clinical implications will be discussed.

Original languageEnglish (US)
Pages (from-to)33-44
Number of pages12
JournalExpert Opinion on Therapeutic Patents
Volume13
Issue number1
DOIs
StatePublished - Jan 1 2003

Fingerprint

Endothelins
Endothelin-1
Pulmonary Hypertension
Heart Failure
Endothelin Receptors
Patents
Vasoconstrictor Agents
Treatment Failure
Mitogens
Atherosclerosis
Therapeutics
Clinical Trials
Hypertension
Endothelin Receptor Antagonists
bosentan

Keywords

  • Chronic heart failure
  • Dual antagonist
  • Hypertension
  • Race
  • Selective antagonist

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Cite this

Development of endothelin receptor antagonists as potential therapeutic agents. / Ergul, Adviye.

In: Expert Opinion on Therapeutic Patents, Vol. 13, No. 1, 01.01.2003, p. 33-44.

Research output: Contribution to journalReview article

@article{8939a286205246f994a2cb9926cba7e0,
title = "Development of endothelin receptor antagonists as potential therapeutic agents",
abstract = "Endothelin-1 (ET-1), a potent vasoconstrictor and mitogen, is associated with several disease states including pulmonary hypertension, systemic hypertension and heart failure. There are two endothelin (ET) receptor subtypes known as ET A and ET B . Selective ET A receptor antagonists, as well as non-selective (dual) ET A /ET B antagonists, represent a new therapeutic target for disease states associated with elevated ET-1 levels. In vivo studies and early phase clinical trials have provided strong evidence that these agents are effective in the treatment of heart failure, essential hypertension, pulmonary hypertension and atherosclerosis. FDA approved the use of the orally active dual antagonist bosentan (Tracleer™, Roche Holding AG) for primary pulmonary hypertension in 2001. Despite important advances in this field, the complexity of biological effects mediated by two different receptor subtypes complicates the use of selective versus dual ET receptor antagonists. The number of patent applications filed in recent years emphasises the importance of this emerging class of therapeutics. From 1997 to date, ∼ 192 patents have been filed. In this review, compounds patented between 1999 and 2002 will be reviewed and clinical implications will be discussed.",
keywords = "Chronic heart failure, Dual antagonist, Hypertension, Race, Selective antagonist",
author = "Adviye Ergul",
year = "2003",
month = "1",
day = "1",
doi = "10.1517/13543776.13.1.33",
language = "English (US)",
volume = "13",
pages = "33--44",
journal = "Expert Opinion on Therapeutic Patents",
issn = "1354-3776",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Development of endothelin receptor antagonists as potential therapeutic agents

AU - Ergul, Adviye

PY - 2003/1/1

Y1 - 2003/1/1

N2 - Endothelin-1 (ET-1), a potent vasoconstrictor and mitogen, is associated with several disease states including pulmonary hypertension, systemic hypertension and heart failure. There are two endothelin (ET) receptor subtypes known as ET A and ET B . Selective ET A receptor antagonists, as well as non-selective (dual) ET A /ET B antagonists, represent a new therapeutic target for disease states associated with elevated ET-1 levels. In vivo studies and early phase clinical trials have provided strong evidence that these agents are effective in the treatment of heart failure, essential hypertension, pulmonary hypertension and atherosclerosis. FDA approved the use of the orally active dual antagonist bosentan (Tracleer™, Roche Holding AG) for primary pulmonary hypertension in 2001. Despite important advances in this field, the complexity of biological effects mediated by two different receptor subtypes complicates the use of selective versus dual ET receptor antagonists. The number of patent applications filed in recent years emphasises the importance of this emerging class of therapeutics. From 1997 to date, ∼ 192 patents have been filed. In this review, compounds patented between 1999 and 2002 will be reviewed and clinical implications will be discussed.

AB - Endothelin-1 (ET-1), a potent vasoconstrictor and mitogen, is associated with several disease states including pulmonary hypertension, systemic hypertension and heart failure. There are two endothelin (ET) receptor subtypes known as ET A and ET B . Selective ET A receptor antagonists, as well as non-selective (dual) ET A /ET B antagonists, represent a new therapeutic target for disease states associated with elevated ET-1 levels. In vivo studies and early phase clinical trials have provided strong evidence that these agents are effective in the treatment of heart failure, essential hypertension, pulmonary hypertension and atherosclerosis. FDA approved the use of the orally active dual antagonist bosentan (Tracleer™, Roche Holding AG) for primary pulmonary hypertension in 2001. Despite important advances in this field, the complexity of biological effects mediated by two different receptor subtypes complicates the use of selective versus dual ET receptor antagonists. The number of patent applications filed in recent years emphasises the importance of this emerging class of therapeutics. From 1997 to date, ∼ 192 patents have been filed. In this review, compounds patented between 1999 and 2002 will be reviewed and clinical implications will be discussed.

KW - Chronic heart failure

KW - Dual antagonist

KW - Hypertension

KW - Race

KW - Selective antagonist

UR - http://www.scopus.com/inward/record.url?scp=0037238070&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037238070&partnerID=8YFLogxK

U2 - 10.1517/13543776.13.1.33

DO - 10.1517/13543776.13.1.33

M3 - Review article

VL - 13

SP - 33

EP - 44

JO - Expert Opinion on Therapeutic Patents

JF - Expert Opinion on Therapeutic Patents

SN - 1354-3776

IS - 1

ER -